MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MMAE-d₈

CAS No. : 2070009-72-0

MCE 国际站：MMAE-d₈

产品活性：MMAE-d₈ 是氘代标记的 MMAE。MMAE 是一种 tubulin 抑制剂，抑制有丝分裂。

研究领域：Cell Cycle/DNA Damage  |  Cytoskeleton  |  Antibody-drug Conjugate/ADC Related

作用靶点：Microtubule/Tubulin  |  ADC Cytotoxin

In Vitro: Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs are generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and the intracellular concentration of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios. LC-MS is used to measure the concentration of MMAE in a parallel cohort of L-82 tumors with an identical treatment regimen. Although tumor volume is not different among treatment groups 3 days after dose, the intratumoral MMAE measurement reveals two patterns. First, intratumoral MMAE concentration increases proportionally to the ADC dose, which correspondes to stronger antitumor activity. Second, the intratumoral MMAE concentration obtained from treatment with both cOKT9-vcMMAE and cAC10-vcMMAE is similar at each dose, consistent with the observation that tumor responded similarly to these two ADCs.

In Vivo: Intratumoral MMAE concentrations consistently correlates with the extent of tumor growth inhibition in tumor xenograft models. IHC analysis reveals that nonbinding control-treated tumors consist of both CD30⁺ and CD30^-cells, presumably because they do not kill either CD30⁺ or CD30^- Karpas 299 cells. Only CD30^- cells are found in cAC10-vcMMAF-treated tumors, illustrating that cAC10-vcMMAF eliminates most CD30⁺ cells. Interestingly, the two tumors that relapses from cAC10-vcMMAE treatment are also found to be CD30^- by the end of study, indicating a small fraction of CD30^- cells might have escaped from bystander killing in these two remaining tumors.

相关产品：Tirbanibulin dihydrochloride  |  Tubulysin IM-3  |  AMXI-5001 hydrochloride  |  Tubulin polymerization-IN-21  |  Dolastatin 10  |  (+)-CBI-CDPI1  |  SB-216  |  MAP4343  |  Duocarmycin GA  |  Tubulin polymerization-IN-8  |  Tubulysin IM-1  |  Maytansinoid B  |  Colchicine-d₃  |  2-Methoxyestradiol-¹³C,d₃  |  Taltobulin  |  Albendazole  |  Duocarmycin DM free base  |  Dideoxy-amanitin  |  Tilavonemab  |  DM4-d₆  |  Camptothecin  |  EGFR-IN-57  |  Epothilone B  |  Epothilone A  |  Maytansinol  |  Docetaxel-d₉  |  N-Me-L-Ala-maytansinol  |  Duocarmycin A  |  Verubulin hydrochloride  |  VcMMAE

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。